BioNTech and OncoC4 have treated the first subject in the Phase III PRESERVE-003 clinical trial of their BNT316/ONC-392 (gotistobart) for non-small cell lung cancer (NSCLC).
The open-label, two-stage, randomised trial will evaluate the safety and efficacy of the antibody as a single agent versus the standard-of-care chemotherapy (docetaxel).
Go deeper with GlobalData
It will enrol 600 metastatic NSCLC patients, who have cancer that advanced under prior therapy with PD-(L)1-inhibitor.
Trial subjects will be enrolled at sites in Europe, the US, Germany, Italy, Belgium and Spain.
Overall survival is the primary endpoint of the trial while progression-free survival, adverse event profile and overall response rate will be evaluated as secondary endpoints.
The trial commencement is based on positive findings from a Phase I/II study that analysed the safety and efficacy of BNT316/ONC-392 monotherapy and along with pembrolizumab in individuals with advanced solid tumours.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIn March this year, the companies entered a strategic partnership agreement under which BioNTech made an upfront payment of $200m to OncoC4.
Co-developed by the companies, BNT316/ONC-392 is an anti-CTLA-4 antibody candidate.
BioNTech chief medical officer and co-founder professor Özlem Türeci said: “We believe this investigational treatment has the potential to become a new option for patients with late-stage NSCLC who have an otherwise poor prognosis.
“Given its specific mode of action, this treatment approach may also be applicable in a synergistic combination with other immunotherapeutic modalities to provide benefit to further patient populations.”
In January this year, BioNTech entered a memorandum of understanding with the UK government to offer tailored messenger ribonucleic acid (mRNA) cancer immunotherapies for up to 10,000 patients by 2030.
